FDA Shelves Risk Evaluation and Mitigation for CAR T Immunotherapies
- July 11, 2025
The Food and Drug Administration (FDA) will no longer require risk evaluation and mitigation strategies (REMS) for immunotherapies used to treat certain blood cancers such as multiple myeloma and certain types of leukemia and lymphoma, the agency announced June 27.
ARTICLE TAGS
You must be logged in to access this content.